Thursday, Aug. 4, 2022 Monoclonal Antibody Prevents Malaria in NIAID Trial of U.S. Adults This image shows the lifecycle of the malaria parasite in a person. One injection of a candidate monoclonal antibody (mAb) known as L9LS was found to be safe and highly protective in U.S. adults exposed to the malaria parasite, according to results from a new NIAID Phase 1 clinical trial published in the New England Journal of Medicine. Additional clinical trials underway in Mali and Kenya, where malaria is endemic, aim to evaluate if a one-time subcutaneous administration of L9LS can prevent infection in infants and children over the course of malaria malaria transmission season. Scientists from NIAID's Vaccine Research Center developed L9LS and led the Phase 1 clinical trial. L9LS is a laboratory-made version of a naturally occurring antibody called L9, which was derived from the blood of a volunteer who had received an investigational malaria vaccine. The antibody prevents malaria by neutralizing the parasites in the skin and blood before they can infect liver cells. National Institute of Allergy and Infectious Diseases  |  National Institutes of Health Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).                             This email was sent to edwardlorilla1986.paxforex@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107